文献速递甲状腺疾病

血清游离三碘甲状腺原氨酸作为左甲状腺素治疗的无甲状腺患者甲状腺激素状态的辅助标志物

Serum free triiodothyronine as an adjunctive marker for thyroid hormone status in athyreotic patients on levothyroxine.
PubMed 文献 · J Clin Endocrinol Metab · 2026-06-17

本研究为单中心回顾性横断面研究,纳入426例接受≥1.2 μg/kg左甲状腺素(LT4)的无甲状腺患者。根据TSH、FT3和FT4分类,多数(58%)患者FT3和FT4正常,18%患者FT3低而FT4正常。在156例未用抗高血脂药物且经倾向性评分匹配的患者中,低FT3者的丙氨酸转氨酶和体重指数显著高于正常FT3者。结论提示低FT3与部分代谢标志物相关,FT3可能提供外周甲状腺激素状态的额外信息。

要点

  • 无甲状腺患者接受LT4治疗时,即使TSH正常,仍有部分患者FT3偏低。
  • 低FT3与丙氨酸转氨酶和体重指数升高相关。
  • FT3可能作为评估外周甲状腺激素状态的辅助标志物。

核心结论

  • 在LT4治疗的无甲状腺患者中,较低的FT3与部分代谢标志物相关,提示FT3可能提供外周甲状腺激素状态的额外信息。

研究设计与样本

  • 单中心回顾性横断面研究,纳入426例接受LT4(≥1.2 μg/kg)的无甲状腺患者。

主要发现

  • 426例患者中,58%血清FT3和FT4正常,21% FT3正常而FT4升高,18% FT3低而FT4正常,2% FT3低而FT4升高。
  • 该分类与反映T4向T3转化效率的FT3/FT4比值差异一致。
  • 在156例未用抗高血脂药物且经倾向性评分匹配(以性别为协变量)的患者中,低FT3者的丙氨酸转氨酶和体重指数显著高于正常FT3者。

临床怎么用

  • 对于LT4治疗的无甲状腺患者,若TSH正常但仍有甲减样症状,可考虑检测FT3以评估外周甲状腺激素状态。

局限性

  • 本研究为单中心回顾性横断面研究,样本量有限。
  • 需要前瞻性研究采用标准化采样并调整混杂因素,以确立FT3作为验证标志物或支持FT3指导的剂量调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Athyreotic patients receiving levothyroxine (LT4) for hypothyroidism sometimes exhibit low serum free triiodothyronine (FT3) levels despite normal TSH, and experience hypothyroid-like symptoms and signs, suggesting reduced peripheral thyroid hormone action. OBJECTIVE: The present study aimed to identify the most reliable biochemical marker for assessing peripheral thyroid hormone status in such patients. METHODS: This was a single-center retrospective, cross-sectional study of athyreotic patients on LT4. Patients were classified according to TSH, FT3 and FT4, and selected metabolic markers potentially influenced by peripheral thyroid hormone status were compared across groups. RESULTS: In 426 athyreotic patients taking ≥1.2 μg/kg of LT4, the majority (58%) of patients exhibited normal serum FT3 and FT4, followed by 21% with normal FT3 and elevated FT4, 18% with low FT3 and normal FT4, and 2% with low FT3 and elevated FT4. This classification corresponded well with the differences in FT3/FT4 ratios that reflect the efficiency of T4 to T3 conversion. Among 156 patients not taking anti-hyperlipidemic drugs and selected with the propensity score matching using gender as a covariate, the metabolic markers of alanine transaminase, and body mass index were significantly elevated in those with low FT3 than in those with normal FT3. CONCLUSION: In our cohort, lower FT3 was associated with selected metabolic markers in LT4-treated athyreotic patients, suggesting that FT3 may provide additional information on peripheral thyroid hormone status in selected patients. Prospective studies with standardized sampling and adjustment for confounding are warranted to establish FT3 as a validated marker or support FT3-guided dosing.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Nagayama Y, Tachibana S, Fukuda T, et al. Serum free triiodothyronine as an adjunctive marker for thyroid hormone status in athyreotic patients on levothyroxine. J Clin Endocrinol Metab. 2026. PMID: 42306861. doi:10.1210/clinem/dgag220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。